Effect of Statins in the Watch and Wait Phase of Chronic Lymphocytic Leukemia

Figures

• 

  FIGURE 1. Markers of CLL progression after statin institution. Clinical records of 57 patients (26 female and 31 male) who commenced statins between 2012 and 2023 in the “watch and wait” phase of management with documented serial LDL measurements, were examined. Records of 19 patients with progressive disease (eventually requiring first‐line therapy) and 21 patients with benign disease (with no evidence of disease progression after prolonged follow‐up) that also had multiple recorded LDL measurements were used as controls. (A) Temporal changes in lymphocytes, β2M, and LDL cholesterol are shown for Patient 11 treated with simvastatin (left panel) and patient P17, who progressed to first‐line therapy but was never exposed to statins (right panel). Note the inflection point indicated by the vertical line seen shortly after starting simvastatin. (B) Lymphocytes, platelets, and β2M values were recorded prior to starting the statin and after the LDL cholesterol had dropped near 2.1 mM. Averages and standard errors of the differences are shown for patients with U‐CLL and patients with M‐CLL. IGHV mutation status was not available for three patients. (C, D) Rates of change of lymphocyte numbers…